UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Journal of clinical oncology, 2006-04, Vol.24 (12), p.1868-1876

2006

Volltextzugriff (PDF)

Focal therapy for prostate cancer: patient selection and evaluation

Expert review of anticancer therapy, 2012-01, Vol.12 (1), p.77-86

2012

Volltextzugriff (PDF)

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model

The Journal of urology, 2009-11, Vol.182 (5), p.2195-2203

2009

Volltextzugriff (PDF)

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

The Journal of urology, 2005-10, Vol.174 (4 Pt 1), p.1242-1247

2005

Volltextzugriff (PDF)

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

European urology, 2014-11, Vol.66 (5), p.829-838

2014

Volltextzugriff (PDF)

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European urology, 2008-05, Vol.53 (5), p.941-949

2008

Volltextzugriff (PDF)

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

European urology, 2007-11, Vol.52 (5), p.1398-1406

2007

Volltextzugriff (PDF)

Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results

The Journal of urology, 1996-02, Vol.155 (2), p.612-615

1996

Volltextzugriff (PDF)

354 LONG TERM RESULTS OF IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRI-VATION IN PATIENTS WITH NO LOCAL TREATMENT FOR T0–4 N0–2 M0 PROSTATE CANCER (EORTC 30891)

The Journal of urology, 2011-04, Vol.185 (4S)

2011

Volltextzugriff (PDF)

352 TIME TO DISEASE PROGRESSION IS NOT AN APPROPRIATE ENDPOINT IN STUDIES OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

The Journal of urology, 2011-04, Vol.185 (4S)

2011

Volltextzugriff (PDF)

Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study

The Journal of urology, 1995, Vol.153 (3S), p.964-973

1995

Volltextzugriff (PDF)

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 MO Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European urology, 2008, Vol.53 (5), p.941-949

2008

Volltextzugriff (PDF)

664: PSA Decline from Baseline is not a Prognostic Factor for Outcome in Hormonally Treated Patients with T0-4N0M0 Prostate Cancer not Suitable for Local Treatment with Curative Intent Treated in Eortc 30891

The Journal of urology, 2006-04, Vol.175 (4S), p.214-214

2006

Volltextzugriff (PDF)

665: Baseline PSA and PSA Doubling Time Predict the Risk of Objective Progression and Death in Patients with T0-4 N0-2 M0 Prostate Cancer on Watchful Waiting

The Journal of urology, 2006-04, Vol.175 (4S), p.215-215

2006

Volltextzugriff (PDF)

60: Urodynamic Behaviour of a Sigmoid Neobladder (Short Distal Detubularized Sigmoid

The Journal of urology, 2004-04, Vol.171 (4S), p.16-16

2004

Volltextzugriff (PDF)

1659: Immediate Versus Deferred Androgen Deprivation in Patients with Asymptomatic Prostate Cancer T0-4 N0-2 M0 Not Suitable for Local Definitive Treatment

The Journal of urology, 2005-04, Vol.173 (4S), p.450-450

2005

Volltextzugriff (PDF)

Perineal radical prostatectomy as monotherapy: ten-year experience

Archivos españoles de urología, 2004-05, Vol.57 (4), p.397

2004

Volltextzugriff (PDF)

Radical Perineal Prostatectomy without Pelvic Lymphadenectomy: Selection Criteria and Early Results

The Journal of urology, 1996-02, p.612-615

1996

Volltextzugriff (PDF)

Original Articles: Bladder Cancer

The Journal of urology, 1995-03, p.964-973

1995

Volltextzugriff (PDF)

Diffuse intratubular undifferentiated germ cell tumor in both testes of a male subject with a uterus and ipsilateral testicular dysgenesis

The Journal of urology, 1980-08, Vol.124 (2), p.286-289

1980

Volltextzugriff (PDF)

Prostatic Urethroplasty - Endoscopic Findings

Seminars in interventional radiology, 1989-03, Vol.6 (1), p.46-56

1989

Volltextzugriff (PDF)

Prostatic Urethroplasty Results Spanish Experience

Seminars in interventional radiology, 1989-06, Vol.6 (2), p.72-78

1989

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(9)

Publikationsform

Artikel
(28)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Urology
(13)
European Urology
(7)
Archivos Españoles De Urología
(2)
Seminars In Interventional Radiology
(2)
Expert Review Of Anticancer Therapy
(1)
Healthcare
(1)
Journal Of Clinical Oncology
(1)
Journal Of Urology
(1)
Urologia Internationalis
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Focal therapy for prostate cancer: patient selection and evaluation

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results

354 LONG TERM RESULTS OF IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRI-VATION IN PATIENTS WITH NO LOCAL TREATMENT FOR T0–4 N0–2 M0 PROSTATE CANCER (EORTC 30891)

352 TIME TO DISEASE PROGRESSION IS NOT AN APPROPRIATE ENDPOINT IN STUDIES OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 MO Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

664: PSA Decline from Baseline is not a Prognostic Factor for Outcome in Hormonally Treated Patients with T0-4N0M0 Prostate Cancer not Suitable for Local Treatment with Curative Intent Treated in Eortc 30891

665: Baseline PSA and PSA Doubling Time Predict the Risk of Objective Progression and Death in Patients with T0-4 N0-2 M0 Prostate Cancer on Watchful Waiting

60: Urodynamic Behaviour of a Sigmoid Neobladder (Short Distal Detubularized Sigmoid

Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin : Multivariate Analysis of Data from Four Randomized CUETO Trials. Commentary

1659: Immediate Versus Deferred Androgen Deprivation in Patients with Asymptomatic Prostate Cancer T0-4 N0-2 M0 Not Suitable for Local Definitive Treatment

Perineal radical prostatectomy as monotherapy: ten-year experience

Radical Perineal Prostatectomy without Pelvic Lymphadenectomy: Selection Criteria and Early Results

Original Articles: Bladder Cancer

Diffuse intratubular undifferentiated germ cell tumor in both testes of a male subject with a uterus and ipsilateral testicular dysgenesis

Prostatic Urethroplasty - Endoscopic Findings

Prostatic Urethroplasty Results Spanish Experience

Suchergebnisse filtern